Entelos Inc.



ENTELOS, Inc.

("Entelos" or "the Company")

Entelos Announces U.S. Patent for its Diabetes Model

Entelos, Inc. (LSE:ENTL) a leading life sciences company building predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, announced today that the U.S. Patent and Trademark Office has
granted U.S. Patent No. 7,353,152 entitled "Method and Apparatus for Computer
Modeling Diabetes" to the Company. This enabling technology forms the basis for
the Entelos(R) Metabolism PhysioLab(R) platform, an innovative and predictive
computer model that can simulate diabetic patients and drug effects and is used
to select the most effective compounds, find the best doses, and support
clinical trial design.

This patent relates to the mathematical and computer modeling of multiple
biological processes underlying the Entelos Metabolism PhysioLab platform. These
processes include, for example, glucose regulation and the metabolism of
protein, fat, and carbohydrates, as well as digestion, absorption, and storage.
The effects of changes in physical activity and diet on such physiological
processes can also be tested. In addition, the model can simulate a wide array
of virtual diabetic patients, from insulin-resistant to severely diabetic
subtypes, and can predict the likely effects of drugs and other treatment
interventions.

The Entelos Metabolism platform, which can be applied to obesity as well as
diabetes research, has already been used successfully with multiple
pharmaceutical partners to select compounds to develop as treatments for
diabetes, find the best doses for clinical trials, identify biomarkers, and
characterize patient subtypes most responsive to certain drugs and drug
combinations.

"This patent represents another milestone in Entelos' intellectual property
strategy and strengthens the Company's leadership position in the quantitative
modeling of human biology generally and diabetes in particular," stated John
Rigsbee, General Counsel of Entelos. "Currently, we have 34 issued patents and
over 120 pending applications worldwide directed to our software modeling
technologies, the methodologies of applying our PhysioLab models to drug
research and development, and the PhysioLab models themselves."

Diabetes is a disease in which the body does not produce or properly use
insulin, a hormone that is needed to convert sugar, starches and other food into
energy in the body. The cause of diabetes continues to be a mystery, although
both genetics and environmental factors such as obesity and lack of exercise
appear to play roles.

Untreated diabetes can lead to many serious long-term complications such a
kidney failure, amputations, blindness, and life-threatening
cardiovascular-related events such as heart attacks and stroke. Diabetes is one
of the fastest growing epidemics in the developing world and is projected to
rise from 84 million in 1995 to 228 million by the year 2025.

"It is well known that a patient's response to a drug depends on multiple
factors, from underlying genetics to diet and lifestyle," stated James Karis,
President and CEO of Entelos. "Diabetes is even more complex, in that multiple
drugs are often used to treat the disease over time. We are pleased to have this
important model patent-protected to sustain our leadership position in the
comprehensive in silico testing of multiple drugs and drug combinations in a
highly variable virtual patient population. We intend to continue making a
significant impact on this disease and on our customers' diabetes-related
programs."

For further information please contact:

Entelos, Inc.
James Karis, President and CEO                    Tel: +1 650 572 5400
Jill Fujisaki, VP Investor Relations

Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson             Tel +44 (0) 20 7466 5000

Notes for Editors

About Diabetes(1)

Diabetes is a disease in which the body does not produce or properly use
insulin. Insulin is a hormone that is needed to convert sugar, starches and
other food into energy needed for daily life. The cause of diabetes continues to
be a mystery, although both genetics and environmental factors such as obesity
and lack of exercise appear to play roles.

There are 20.8 million children and adults in the United States, or 7% of the
population, who have diabetes. It is one of the fastest growing epidemics in the
developing world as well, and it is projected to rise from 84 million in 1995 to
228 million by the year 2025. Rapidly industrializing areas such as India, the
Middle East, and Southeast Asia will likely bear the greatest burdens from
diabetes, and it is estimated that India alone will have an estimated 73.5
million diabetics by 2025.

Diabetes can lead to many serious long-term complications such a kidney failure,
amputations, blindness, and cardiovascular-related events such as heart attacks
and stroke.

1. Sources: the American Diabetes Association and "Pharma2020: The vision" by
PricewaterhouseCoopers, 2007.

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The Company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Entelos Regs Charts.
Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Entelos Regs Charts.